Core Viewpoint - The implementation of the new basic medical insurance directory and the first commercial insurance innovative drug directory starting January 1, 2026, will enhance the accessibility and affordability of innovative treatments like Baihe An (Zanidatamab) for patients with HER2-positive biliary tract cancer (BTC) [1][2]. Group 1: Drug Approval and Clinical Value - Zanidatamab is the first and only dual-specific antibody approved in China for targeting HER2 in high-expressing BTC, highlighting its unique clinical value [1][4]. - The drug has shown a 51.6% objective response rate (ORR) in previously treated, unresectable HER2-positive advanced or metastatic BTC patients, with a median overall survival (mOS) of 18.1 months [4]. Group 2: Insurance Coverage and Patient Access - The drug is covered under various "Hui Min Bao" commercial supplementary medical insurance projects across multiple regions, allowing eligible patients to receive significant reimbursement for treatment costs [2]. - The combination of the commercial insurance innovative drug directory and "Hui Min Bao" is expected to significantly improve the accessibility and affordability of this innovative drug for more patients [2]. Group 3: Broader Implications and Future Developments - The company aims to address the unmet medical needs in advanced BTC treatment, which has limited options and poor prognosis, by providing innovative therapies that enhance patient quality of life [4][8]. - Zanidatamab is also being developed for other gastrointestinal tumors, including HER2-positive metastatic gastric and colorectal cancers, indicating its potential for broader applications in oncology [5][6].
22省市“惠民保”参保胆道癌患者将享受靶向治疗商保报销